このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

PharmaSGP Holding マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Natalie Weigand

最高経営責任者

€865.0k

報酬総額

CEO給与比率	34.7%
CEO在任期間	4.3yrs
CEOの所有権	n/a
経営陣の平均在職期間	データなし
取締役会の平均在任期間	4.3yrs

経営陣の近況

Recent updates

Shareholders Will Be Pleased With The Quality of PharmaSGP Holding's (ETR:PSG) Earnings

May 06

Some Shareholders Feeling Restless Over PharmaSGP Holding SE's (ETR:PSG) P/E Ratio

Mar 02

PharmaSGP Holding SE Just Beat Revenue Estimates By 25%

Dec 02

One Analyst Just Shaved Their PharmaSGP Holding SE (ETR:PSG) Forecasts Dramatically

Feb 16

We Think PharmaSGP Holding's (ETR:PSG) Statutory Profit Might Understate Its Earnings Potential

Jan 26

Do Institutions Own PharmaSGP Holding SE (ETR:PSG) Shares?

Dec 04

CEO報酬分析

PharmaSGP Holding の収益と比較して、Natalie Weigand の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	€18m
Dec 31 2023	€865k	€300k	€16m
Sep 30 2023	n/a	n/a	€15m
Jun 30 2023	n/a	n/a	€14m
Mar 31 2023	n/a	n/a	€13m
Dec 31 2022	€314k	€250k	€12m
Sep 30 2022	n/a	n/a	€11m
Jun 30 2022	n/a	n/a	€11m
Mar 31 2022	n/a	n/a	€11m
Dec 31 2021	€272k	€250k	€11m
Sep 30 2021	n/a	n/a	€8m
Jun 30 2021	n/a	n/a	€8m
Mar 31 2021	n/a	n/a	€9m
Dec 31 2020	€279k	€258k	€11m
Sep 30 2020	n/a	n/a	€16m
Jun 30 2020	n/a	n/a	€17m
Mar 31 2020	n/a	n/a	€17m
Dec 31 2019	€141k	€141k	€17m

報酬と市場: Natalieの総報酬 ($USD 928.81K ) は、 German市場 ($USD 1.07M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Natalieの報酬は過去 1 年間で 20% 以上増加しました。

CEO（最高経営責任者

Natalie Weigand (43 yo)

4.3yrs

在職期間

€865,000

報酬

Ms. Natalie Weigand serves as the Chief Executive Officer at PharmaSGP Holding SE since June 2020 and also serves as a Member of Management Board since March 04, 2020. She joined the FUTRUE Group as the le...

取締役

名称	ポジション	在職期間	報酬	所有権
Axel Rebien	Member of the Supervisory Board	4.1yrs	€50.00k	データなし
Madlena Hohlefelder	Deputy Chairwoman of the Supervisory Board	4.3yrs	データなし	48.95% € 130.3m
Clemens Fischer	Chairman of the Supervisory Board	4.3yrs	データなし	データなし

4.3yrs

平均在職期間

49yo

平均年齢

経験豊富なボード: PSGの取締役会は経験豊富であると考えられます ( 4.3年の平均在任期間)。

PharmaSGP Holding マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

PharmaSGP Holding SE, Annual General Meeting, Jun 26, 2024

PharmaSGP Holding SE, Annual General Meeting, Jun 15, 2022

Recent updates

Price target increased by 9.2% to €38.75

PharmaSGP Holding SE, Annual General Meeting, Jun 26, 2024

Shareholders Will Be Pleased With The Quality of PharmaSGP Holding's (ETR:PSG) Earnings

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Dividend of €1.36 announced

PharmaSGP Holding SE Proposes Dividend for the Financial Year 2023

PharmaSGP Holding SE Proposes Dividend for the Financial Year 2023

PharmaSGP Holding SE to Report Fiscal Year 2023 Results on Apr 29, 2024

Some Shareholders Feeling Restless Over PharmaSGP Holding SE's (ETR:PSG) P/E Ratio

Investor sentiment improves as stock rises 15%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Second quarter 2023 earnings released: EPS: €0.33 (vs €0.25 in 2Q 2022)

Upcoming dividend of €0.49 per share at 1.7% yield

New minor risk - Financial position

Consensus EPS estimates increase by 10%

Price target increased by 7.2% to €37.00

Price target increased by 9.2% to €35.50

PharmaSGP Holding SE (XTRA:PSG) commences an Equity Buyback Plan, under the authorization approved on May 28, 2020.

PharmaSGP Holding SE to Report Q1, 2022 Results on Sep 15, 2022

PharmaSGP Holding SE, Annual General Meeting, Jun 15, 2022

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Consensus EPS estimates increase by 11%

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

PharmaSGP Holding SE Provides Revenues Guidance for the Financial Year 2022

PharmaSGP Proposes Dividend for 2021

PharmaSGP Holding SE to Report Fiscal Year 2021 Results on Mar 15, 2022

PharmaSGP Holding SE Just Beat Revenue Estimates By 25%

Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Second quarter 2021 earnings released: EPS €0.25 (vs €0.32 in 2Q 2020)

Investor sentiment improved over the past week

Consensus forecasts updated

First quarter 2021 earnings released: EPS €0.10 (vs €0.27 in 1Q 2020)

PharmaSGP Holding SE Provides Earnings Guidance for 2021

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS €0.89 (vs €1.39 in FY 2019)

Analysts lower EPS estimates to €0.95

One Analyst Just Shaved Their PharmaSGP Holding SE (ETR:PSG) Forecasts Dramatically

PharmaSGP Holding SE to Report Fiscal Year 2020 Final Results on Apr 22, 2021

We Think PharmaSGP Holding's (ETR:PSG) Statutory Profit Might Understate Its Earnings Potential

New 90-day low: €19.76

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Market pulls back on stock over the past week

Do Institutions Own PharmaSGP Holding SE (ETR:PSG) Shares?

Analysts lower EPS estimates to €1.13

New 90-day low: €27.00

New 90-day low: €28.75

First half earnings released

PharmaSGP Holding SE to Report First Half, 2020 Final Results on Sep 30, 2020

PharmaSGP Holding SE to Report First Half, 2020 Results on Sep 10, 2020

PharmaSGP Holding SE to Report Q3, 2020 Results on Nov 30, 2020

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24